Assignee profile:

ALTEOGEN, INC

City:

Daejeon

Country:

South Korea

Published Applications:

22

Last publication date:

2025-12-04

Patent Grants:

16

Last grant date:

2026-05-05

Top Inventors for applications by ALTEOGEN, INC

These are the the leading inventors for applications assigned to ALTEOGEN, INC:

Recent patent applications by ALTEOGEN, INC

ALTEOGEN, INC based in Daejeon, KR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2025-12-04
US20250368976A1
Chemistry; metallurgy

NOVEL HYALURONIDASE VARIANTS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

#2 | 2025-05-01
US20250136964A1
Chemistry; metallurgy

METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE

#3 | 2025-04-24
US20250129352A1
Chemistry; metallurgy

METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE

#4 | 2025-01-09
US20250009850A1
Human necessities

PHARMACEUTICAL COMPOSITION COMPRISING HUMAN HYALURONIDASE PH20 AND DRUG

#5 | 2023-08-10 ✅ Patent 12,618,055 granted on 2026-05-05
US20230250408A1
Chemistry; metallurgy

NOVEL HYALURONIDASE VARIANTS WITH IMPROVED STABILITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

#6 | 2023-06-08 ✅ Patent 12,221,638 granted on 2025-02-11
US20230174963A1
Chemistry; metallurgy

Method for producing recombinant hyaluronidase

#7 | 2022-11-03
US20220348636A1
Chemistry; metallurgy

METHOD FOR PRODUCING FUSION PROTEIN HAVING IGG FC DOMAIN

#8 | 2022-04-07 ✅ Patent 12,090,210 granted on 2024-09-17
US20220105197A1
Human necessities

Antibody-drug conjugate comprising modified antibody

#9 | 2021-11-25 ✅ Patent 12,570,766 granted on 2026-03-10
US20210363270A1
Chemistry; metallurgy

PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS INJECTION COMPRISING HUMAN HYALURONIDASE PH20 VARIANT AND DRUG

#10 | 2021-05-27 ✅ Patent 12,371,683 granted on 2025-07-29
US20210155913A1
Chemistry; metallurgy

NOVEL HYALURONIDASE VARIANTS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

#11 | 2021-01-14 ✅ Patent 11,866,492 granted on 2024-01-09
US20210009685A1
Chemistry; metallurgy

Antibody specifically binding to FOLR1 and uses thereof

#12 | 2020-12-24 ✅ Patent 11,981,719 granted on 2024-05-14
US20200399340A1
Chemistry; metallurgy

Growth hormone receptor antagonists and fusion proteins thereof

#13 | 2020-08-13 ✅ Patent 11,235,065 granted on 2022-02-01
US20200254111A1
Human necessities

Antibody-drug conjugate comprising modified antibody

#14 | 2018-10-18 ✅ Patent 11,414,476 granted on 2022-08-16
US20180298078A1
Chemistry; metallurgy

Method for producing fusion protein having IgG Fc domain

#15 | 2017-05-04
US20170119903A1
Human necessities

MODIFIED ANTIBODY IN WHICH MOTIF COMPRISING CYSTEINE RESIDUE IS BOUND, MODIFIED ANTIBODY-DRUG CONJUGATE COMPRISING THE MODIFIED ANTIBODY, AND PRODUCTION METHOD FOR SAME

#16 | 2016-12-29 ✅ Patent 9,982,032 granted on 2018-05-29
US20160376342A1
Chemistry; metallurgy

Stable liquid formulation of fusion protein with IgG Fc domain

#17 | 2016-04-28 ✅ Patent 9,821,059 granted on 2017-11-21
US20160114036A1
Human necessities

Composition for stabilizing protein and pharmaceutical formulation comprising the same

#18 | 2016-04-14 ✅ Patent 9,814,782 granted on 2017-11-14
US20160102148A1
Chemistry; metallurgy

Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same

#19 | 2015-11-05 ✅ Patent 9,474,803 granted on 2016-10-25
US20150313996A1
Human necessities

Composition for stabilizing fusion protein in which protein and FC domain are fused

#20 | 2015-05-07 ✅ Patent 9,902,753 granted on 2018-02-27
US20150126715A1
Chemistry; metallurgy

Method of purifying a long-acting human growth hormone

#21 | 2014-12-18 ✅ Patent 9,051,395 granted on 2015-06-09
US20140371160A1
Chemistry; metallurgy

Alpha-1 antitrypsin variant, preparation method thereof and use thereof

#22 | 2012-04-19 ✅ Patent 9,012,606 granted on 2015-04-21
US20120094356A1
Chemistry; metallurgy

In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasng in vivo half-life using same

Also check out ALTEOGEN, INC.'s (Daejeon, South Korea) applicant profile with 19 patent applications submitted.

AssigneeID:

84928 ⎘